Recommended

GSK appoints new CEO
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

MSD Ireland’s €1b facility investment achieves new milestone

0
SHARES

Opening of a new facility in Dunboyne, Co. Meath and expansion of MSD’s first vaccines operation outside of the US enables MSD Ireland to help address the demand for vaccines and medicines worldwide.

MSD Ireland’s €1b facility investment achieves new milestone

Credit: rafapress / Shutterstock.com

MSD Ireland’s new, state-of-the-art facility in Dunboyne, Co. Meath has opened. Additionally, the company has announced expansion of its Carlow site. In total, both projects represent an investment of over €1 billion.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

In total, both projects represent an investment of over €1 billion”

MSD Carlow runs as filling site for the launch and commercial supply of vaccines, biologics, and small molecule drug products. Opened in 2008, the facility was MSD’s first vaccines operation outside of the US. The new expansion will strengthen MSD’s global manufacturing capabilities to meet increased demand for MSD’s medicines and vaccines.

MSD Dunboyne in Co. Meath is MSD’s first biologics drug substance single use commercialisation facility. This recent investment will significantly accelerate the time it takes to bring a medicine to market, according to MSD Ireland.

As a result of the investment, 670 new jobs across both sites have been created. There are currently 100 active vacancies, covering key roles in sectors including engineering, science, manufacturing operations and quality.

“These two facilities will yield substantial enhancements to our manufacturing capabilities, enabling our global network to better address the always-evolving demand for vaccines and medicines worldwide,” remarked Sanat Chattopadhyay, Executive Vice President & President, Manufacturing Division, MSD.

MSD Ireland’s investment “reinforces the {Irish} Government’s commitment to balanced regional development, and further enhances Ireland’s global status in the pharmaceutical sector,” stated Taoiseach Leo Varadkar TD.

Share via
Share via